Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection

BACKGROUND: Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated durable efficacy and a manageable safety profile in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in the ELIANA pivotal trial and re...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Hall, Erin M, Yin, Dwight E, Goyal, Rakesh K, Ahmed, Atif A, Mitchell, Grace S, St. Peter, Shawn D, Flatt, Terrie G, Ahmed, Ibrahim A, Li, Weijie, Hendrickson, Richard J, August, Keith J, Myers, G Doug
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Case Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7818837/
https://ncbi.nlm.nih.gov/pubmed/33472856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001225
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items